Latest News

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

A nasal vaccine against whooping cough shows promise in blocking infection and enhancing respiratory immunity, offering a needle-free solution.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

Only Humans Can Ensure AI Is Ethical and Unbiased

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

Semaglutide shows significant weight loss and reduces obesity-related health risks, offering a promising solution for effective weight management.

The new year can present challenges to health-system pharmacy.

Metformin may hinder exercise benefits, impacting blood vessel function and insulin control, raising concerns for diabetes management during physical activity.

The Latest Kaiser Family Foundation Employer Health Benefits Survey Has Unsurprising but Consequential Findings

Integrating a pharmacist into multidisciplinary settings allowed for more thorough LDL-C lowering in unique settings.

Pharmacists’ expertise is vital to AI’s safe integration into medication management. A growing array of resources and training supports pharmacists’ engagement with this new technology.

Researchers unveil a pharmacist-led intervention to enhance hypoglycemia management in older adults with type 2 diabetes, improving patient outcomes.

The FDA lifts the black box warning on hormone replacement therapy, empowering women with new options for managing menopause symptoms.

Recent analysis reveals no significant link between maternal acetaminophen use and increased autism or ADHD risk, challenging previous health claims.

Inclisiran significantly enhances LDL-C goal attainment in post-acute coronary syndrome patients, improving lipid management outcomes.

A bidirectional relationship was observed between long COVID and cardiovascular disease in survey results presented at IDWeek.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Consistent use of continuous glucose monitoring (CGM) significantly improves glycemic control in adults with type 2 diabetes (T2D).